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Abstract 
Bovine Respiratory Disease (BRD) continues to be one of the largest animal health 
concerns in the cattle industry.  BRD is a multifaceted group of pathogens, both viral and 
bacterial, that take advantage of an immune compromised calf to cause disease.  This study took 
aim at comparing metaphylactic treatments for BRD in both the feedlot and pasture setting.   
In the feedlot study, heifers (n=579, 403.7 ± 27.4 lbs) from Southwest Texas were 
identified as being high risk for BRD and shipped  to the  Clayton Livestock Research Center in 
Clayton, NM.  Cattle were randomly allocated within truck load lots into 18 to 20 head treatment 
pens (30 pens; 3 treatments; 10 reps). Cattle were given one of three metaphylactic treatments 
based on the randomly assigned treatment for their pen within a replicate.  The three antibiotic 
treatments administered at initial processing were: 1) Tulathromycin (2.5 mg/kg), 2) Tilmicosin 
(13.3 mg/kg), and 3) Gamithromycin (6.0 mg/kg).  Cattle were fed a typical commercial starter 
diet for the first 56-60 d with a step-up ration change at day 28.  At the end of the feeding period, 
pens were weighed and body weights recorded.  Dry Matter Intake, morbidity, and mortality 
were recorded by CLRC personnel daily.  Cattle administered tulathromycin had higher daily 
gains than cattle administered gamithromycin by 0.29 lbs/d (P<.01) and tended (P=0.09) have 
higher daily gains than cattle that received tilmicosin by 0.18 lbs/d.  Tulathromycin treated cattle 
tended (P = 0.12) to have improved feed efficiency compared to gamithromycin treated cattle.  
Cattle that received tulathromycin (5.2%) had lower morbidity rates (P < .02) than tilmicosin 
(14.6%) and gamithromycin (12.79%) treated cattle.  There were no treatment differences in dry 
matter intake or mortality in cattle. 
  
For the wheat pasture study, heifers (n=120, 393.2 ± 28.6 lbs) from the same origin and 
risk were shipped to the CLRC and processed before being trailed to a nearby wheat pasture.  
Cattle were randomly assigned into three treatment groups (3 treatments, 40 reps), and were 
given one of three metaphylactic treatments.  The three antibiotic treatments administered at 
initial processing were: 1) Tulathromycin (2.5 mg/kg), 2) Tilmicosin (13.3 mg/kg), and 3) 
Gamithromycin (6.0 mg/kg).  Cattle were allowed to graze on wheat for 54 days with free-choice 
Hi-Pro mineral mixed with Lasalocid, an ionophore.  After 54 days on wheat pasture, the cattle 
were trailed back to the CLRC facilities and final individual weights were recorded.  Morbidity 
and mortality were recorded daily by CLRC personnel.  No differences were identified for ADG 
(P=0.98), morbidity (P=0.46) or mortality (P=0.36) among the three treatment groups. 
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Chapter 1 - Literature Review: Bovine Respiratory Disease 
 Bovine Respiratory Disease 
 
In an extensive review article written by Griffin et al in 2010, they outlined the bacterial 
pathogens associated with bovine respiratory disease complex (BRDC), as well as the pathology 
and clinical signs associated with the disease.
1
  This article lists Mannheimia haemolytica, 
Pasteurella multocida, Histophilus somni, and Mycoplasma bovis as the important bacterial 
pathogens of BRDC.  It also states that many factors, including stress, viral, and/or parasitic 
infections can suppress the calves’ immune response and allow these bacterial pathogens to 
replicate.  Mannheimia haemolytica is believed to be the main bacterial pathogen most often 
associated with BRDC.  Clinical signs of BRDC have proven to be difficult to diagnose until 
many days after disease onset due to the prey response of cattle in which they mask illness to 
avoid detection by predators.  This behavior allows cattle to mask early symptoms from feedlot 
personnel.  Clinical signs may include nasal and ocular discharge, depression, anorexia, fever, 
tachypnea, and coughing.
1
  More severe cases will show respiratory distress, encrusted muzzles, 
excessive tear production, and dyspnea.  The main cause of death associated with BRDC is acute 
pleuropneumonia.  The main pathological lesions described in this article include lungs with 
bilateral consolidation with firm and heavy texture.  Fibrinous adhesions to the parietal and 
visceral pleura are observed with acute fibrinous and serofibrinous pleuritis.  In chronic cases, 
coagulation necrosis surrounded by progressively worse pale fibrous tissue are seen.  The article 
concludes that these four bacterial pathogens are the most significant cause of morbidity and 
mortality of BRDC, and a better understanding of these pathogens’ virulence factors and 
pathogenesis, may lead to better management, therapeutics, and vaccines.
1
 
2 
 
A trial by Schneider et al in 2009, used treatment records and lung lesion scores to assess 
the impact of BRDC on performance and carcass traits.  Treatment records from 5,976 animals 
and lung lesions from a subset number of 1,665 were used for analysis.  The observed incidence 
rate of BRDC at the feedyard was 8.17%.  Of cattle never treated for BRD 60.6% had lung 
lesions present after harvest; also, 74% of cattle treated at least once for BRD had lung lesions, 
indicating that 26% of cattle treated for BRD did not have lung lesions.  Performance decreased 
in cattle that were treated for BRDC compared to those never treated.
2
   
 
 Economic Implications 
 
Revisiting the study conducted by Schneider et al in 2009, economic implications of 
BRD were also evaluated.  The results of the specific cattle, based on carcass premiums and 
actual price received, showed that cattle treated once, twice, or three or more times returned 
$23.23, $30.15, and $54.01, respectively, less than untreated cattle.  Cattle not suffering from 
BRD were more valuable in this study (P < 0.01).  These costs do not include the added losses 
due to medicine cost, labor, veterinary fees, and death loss.
2 
Brooks et al evaluated the economic effects of BRD on feedlot calves in 2011.  During 
the backgrounding phase (initial 63 days in feedyard), heifers treated zero, once, twice, or three 
times had $111.12, $92.51, $59.98, and $20.62, respectively, greater net returns (P < 0.01) than 
those considered chronic (treated four or more times).
3
  This finding was  in agreement with a 
study by Fulton et al. in 2002 showing calves never treated for BRD yielded greater returns than 
those treated one or more times.
4
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Mean profit per head, in a study comparing metaphylactic treatments of two dosages of 
tilmicosin with an untreated control, revealed greater returns (P = 0.02) on both tilmicosin 
treatment groups (20 mg/kg dose = $84.61, 10 mg/kg dose = $45.19) than the untreated controls 
(-$41.41).
5
   Their second study, compared identical treatment groups as in the first study but in a 
difference location, numerically greater returns  (P > 0.05) were shown in cattle treated with 
metaphylactic tilmicosin (20 mg/kg dose = $376.33, 10 mg/kg dose = $365.73) than untreated 
controls ($331.15).
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 Macrolide Class of Antibiotics 
 
At the time of this study, the single dose macrolide antibiotics approved for control of 
BRD in feedlot cattle are: tilmicosin, tulathromycin, and gamithromycin.  Macrolides belong to a 
class of antibiotics that contain a lactone ring in their molecular structure.  Gamithromycin and 
tulathromycin contain 15-member rings, and tilmicosin contains a 16-member ring.  Their 
pharmacokinetic and pharmacodynamic properties of having a high volume of distribution and 
being dependent on time spent above the minimum inhibitory concentration (MIC) are favorable 
for their metaphylactic use.  A high volume of distribution allows for a smaller dose to be 
administered to reach a high concentration in the target tissue.  Macrolides are bacteriostatic and 
work by invading the bacterial cell membrane and binding to the 50s ribosome subunit, 
preventing protein synthesis.  Translocation between the 50s and 30s ribosome is interrupted, 
creating early detachment of incomplete peptide chains.  Without these proteins essential for cell 
survival, the bacterium dies.
6
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Lombardi et al in 2011 studied the pharmacokinetic properties of tilmicosin.  In this 
experiment, they used light weight and heavy weight cattle, and two dosages (10 mg/kg and 20 
mg/kg).  In light weight cattle receiving 10 mg/kg tilmicosin, blood concentrations reached a 
maximum of 0.714 μg/ml  at 0.571 h post-injection.  In light weight cattle receiving 20 mg/kg 
tilmicosin, blood concentrations reached a maximum of 1.059 μg/ml  at 1.571 h post-injection.  
The half-life of tilmicosin in this experiment was between 30.83 and 31.15 hours across all 
treatment groups.
7
   
In 2004, Nowakowski et al studied the pharmacokinetic properties of tulathromycin.   
Two studies were completed using multiple groups of cattle.  Serum and lung tissue analysis was 
performed to determine the desired parameters.  Results of both studies indicated that peak 
concentrations of tulathromycin were higher in the lungs (4,100 ng/g) than in plasma 
(approximately 500 ng/ml), and achieved these concentrations within 24 h of administration.  
Although the results varied among treatment groups, in the first study, the elimination half-life 
ranged between 58 and 99 h.
8 
Giguere et al in 2011 studied the pharmacokinetic properties of gamithromycin.  They 
studied concentrations of gamithromycin in plasma, pulmonary epithelial lining fluid (PELF), 
bronchoalveolar lavage cells (BAL), and lung tissue.  Results showed that the half-life of 
gamithromycin in the plasma of cattle was 62 h.  It took gamithromycin one hour to reach a peak 
concentration of 0.433 μg/ml in the plasma.  In the PELF, the half-life was 50.6 h, and it took 24 
h to reach a peak concentration of 4.61 μg/ml.  BAL cells showed a longer half-life at 125 h, and 
it took 24 h to reach a peak concentration of 17.8 μg/ml.  Finally, after measuring gamithromycin 
properties in the lungs, results indicated a half-life of 93 h, and it took 12 h to reach a peak 
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concentration of 27.8 μg/g.  These results are similar to other macrolides, as lung concentrations 
are much higher than plasma concentrations.
9 
These three articles measuring the pharmacokinetic properties of three of the most 
commonly used macrolides shows similar half-lives between tulathromycin and gamithromycin, 
with the half-life of tilmicosin being one half to one third shorter in duration.   
 
 Metaphylaxis 
 
In a trial conducted in Italy in 2010 by Sgoifo Rossi et al, they compared metaphylactic 
treatments of gamithromycin with untreated controls, oxytetracycline, and tulathromycin.  
Gamithromycin treated cattle had a lower (P < 0.0001) morbidity rate (4.8%) than the untreated 
controls (34.4%).  Similarly, gamithromycin treated cattle had a lower (P < 0.0001) morbidity 
rate (1.7%) than oxytetracycline treated cattle (14.5%).  In their third metaphylactic trial, the 
morbidity rate of cattle receiving gamithromycin (9.3%) was  lower (P = 0.006) than cattle 
receiving tulathromycin (14.6%).
10 
Booker et al in 2007 evaluated the efficacy of tulathromycin as a metaphylactic 
antimicrobial in feedlot calves.  Treatment groups consisted of calves at high risk for BRD 
receiving tulathromycin, tilmicosin, or oxytetracycline.  In this experiment, calves were followed 
all the way to harvest.  Slaughter weight, weight gain, carcass weight, days on feed, and daily dry 
matter intake were significantly (P < 0.05) higher in calves pre-treated with tulathromycin 
compared to tilmicosin and oxytetracycline treated calves.  No difference (P > 0.05) was found 
between treatment groups for dressing percentage.  Both morbidity and mortality rates were 
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significantly lower (P < 0.05) for calves treated with tulathromycin than those treated with 
tilmicosin and oxytetracycline.
11 
In an attempt to evaluate the efficacy of metaphylaxis versus fever-based treatments and 
negative controls, Galyean et al in 1995 completed three trials with high risk calves using 
tilmicosin.  The first two trials consisted of only two treatment groups: metaphylactic treatments 
with tilmicosin and no treatment.  In both trials 1 and 2, no differences were found for average 
daily gain (P > 0.05) and dry matter intake (P > 0.05); however, mass treatment did decrease (P < 
0.01) the prevalence of calves treated for BRD from 46.4% in controls to 0% in calves 
metaphylactically treated on arrival.
12
  In the third trial, a third treatment group was implemented 
where only calves with rectal temperatures above 39.7 °C (103.5 °F) were treated with tilmicosin 
on arrival.  Results of this trial showed increased average daily gains (P < 0.01) during the initial 
28 day feeding period.  Dry matter intake was greater (P < 0.05) and feed conversion was lower 
(P < 0.03) for both the metaphylaxis treatment group and calves treated based on rectal 
temperature when compared with the negative control group.  Morbidity rates were significantly 
decreased (P < 0.01) from calves not treated (43.6%) to calves mass treated (11.9%) and calves 
treated based on rectal temperatures (12.9%).  No differences were found between groups of 
mass treated calves and groups of calves on treated based on rectal temperature.
12 
Three years after the Galyean et al trial, Vogel et al in 1998 completed a similar study 
with high risk calves also using tilmicosin.  This trial consisted of three treatment groups: 1) 
nonmedicated control group, 2) fever-based medicated group where calves were treated with 
tilmicosin if their rectal temperatures exceeded 104 °F, and 3) metaphylaxis group where all 
calves received tilmicosin.  Results indicated that both fever-based and metaphylactic treatments 
with tilmicosin decreased the morbidity and mortality; as well as, increased gains, of high risk 
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calves when compared to the negative control treatment group.  Finally, results also indicated 
that fever-based treatments with tilmicosin were less effective at decreasing BRD incidence than 
metaphylaxis.
13
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 Study Objectives 
 
Due to BRD being the most prevalent and economically costly disease in the cattle 
industry, it becomes important to assess the methods used to lessen its effects.  With a wide 
variety of antibiotics available, and the growing popularity of metaphylaxis, many studies are 
being performed, to compare effectiveness.  These two studies are aimed at comparing three 
popular macrolides in a specific class of calves in a specific environment when used as 
metaphylactic treatments for BRD.  The first study aims at comparing the three macrolides on 
performance, feed conversion, morbidity and mortality in high risk heifers entering a feedyard.  
The second study compares performance, morbidity and mortality in high risk heifers being on 
wheat pasture.   
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Chapter 2 - Comparison of Gamithromycin, Tilmicosin and 
Tulathromycin: Metaphylactic Treatments in High Risk Calves for 
Bovine Respiratory Disease 
  
 Introduction 
 
Bovine Respiratory Disease (BRD) continues to be one of the largest animal health 
concerns in the cattle industry.
1,2,3
  Bovine Respiratory Disease is caused by a group of 
pathogens, both viral and bacterial, that take advantage of an immune-compromised calf to cause 
disease.
1
  The viral pathogens include Infectious Bovine Rhinotracheitis (IBR), Bovine 
Respiratory Syncytial Virus (BRSV), Parainfluenza-3 (PI3), and Bovine Viral Diarrhea (BVD – 
Type I and II) (Griffin et al, 2010).  Bacterial pathogens consist of Mannheimia haemolytica, 
Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
1
  Identifying BRD in cattle 
can be very difficult.  Of cattle never treated for BRD, 60.6% had lung lesions present after 
harvest; also, 74% of cattle treated at least once for BRD had lung lesions, indicating that 26% of 
cattle treated for BRD did not have lung lesions.
2
    
 
The cost of BRD to the beef industry due to death, poorer conversions, and therapy cost 
each year is estimated to be between $800 and $900 million.
14
  As the number of treatments 
increased during the backgrounding phase, the net returns decreased; also, animals treated for 
BRD three or more times have lower average daily gain (ADG) than animals treated less than 
three times. Calves treated metaphylactically with tilmicosin had greater (P < .01) economic 
return than controls.
5
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Macrolides belong to a class of antibiotics that contain a lactone ring in their molecular 
structure.  Gamithromycin and tulathromycin contain 15-member rings, and tilmicosin contains a 
16-member ring.  Their pharmacokinetic and pharmacodynamic properties of having a high 
volume of distribution and being dependent on time spent above the minimum inhibitory 
concentration (MIC) are favorable for their metaphylactic use.  Macrolides are bacteriostatic and 
work by invading the bacterial cell membrane and binding to the 50s ribosome subunit, 
preventing protein synthesis.
6
  
Two experiments were completed comparing gamithromycin, tilmicosin, and 
tulathromycin in both a feedyard and pasture setting.  The objectives of these experiments were 
to compare the efficacy of the three macrolides, administered metaphylactically, on health and 
performance of heifers at high risk for developing BRD. 
   
11 
 
Materials and Methods 
 
 Feedyard Study 
Animals 
All animals were treated and handled in accordance with protocols approved by the New 
Mexico State University Institutional Animal Care and Use Committee (# 2011-034). 
 Over a 17 day period starting October 27, 2011, individual loads of heifers (n = 592, 
403.3 + 27.4 lbs) identified as being high risk (defined as comingled, long haul, and light weight 
calves with sale barn origin) for BRD arrived at the Clayton Livestock Research Center (CLRC) 
near Clayton, NM.  The heifers consisted of a variety of hide colors and of mixed genetics.  Each 
load (114-120 animals per load) was unloaded and heifers weighed individually before being 
placed in an arrival pen with free-choice access to long-stemmed hay, a minimal amount (< 1.0 
lb/head as fed) of starter ration and ad libitum access to water.  After 24-48 h rest, cattle were 
individually processed and placed in home pens.  Within arrival group, cattle were randomly 
allocated into two replicates, and then randomized to one of three treatment groups (n = 18-20 
animals per pen, depending on load size).  Treatments were: tulathromycin
a
, tilmicosin
b
, and 
gamithromycin
c
.  All arrival groups were fed for 56-60 days depending on when the weather 
allowed for final weights to be measured. 
 
Treatments 
Treatment groups consisted of the following: 1) tulathromycin (n = 192; 2.5mg/kg, 1.1 
ml/100 lb), 2) tilmicosin (n = 193; 13.2 mg/kg, 2 ml/100 lb), 3) gamithromycin (n = 194; 6 
mg/kg, 1.82 ml/100 lb).  Within arrival group, cattle were randomly assigned to treatment group 
12 
 
as they were processed, in groups of three animals each, and placed in the appropriate sorting 
pen.  Once sorted, each treatment group was moved to an assigned soil-surfaced pen (40 ft x 115 
ft, with 36 ft bunk line; 19-20 animals/pen).  Each heifer had about 22 inches of bunk space.  
Water was supplied to each pen with a bunk line continuous flow water tank.  Pen served as the 
experimental unit.  The study consisted of three treatments with ten replicates per treatment. 
During initial processing, each heifer was weighed, vaccinated for BVD (Type I and II)
d
, IBR, 
BRSV, and PI3
e
, given a doramectin
f
 injection and oral albendazole
g
, and implanted with 100 mg 
progesterone and 10 mg estradiol benzoate
h
.  Each animal received an individual identification 
ear tag, a tag identifying treatment assignment, and any horns, if present were tipped to 
approximately 2.54 cm diameter. 
 
Feeding 
Heifers were started on a receiving diet composed of 20% ground corn, 57% wet corn 
gluten feed
i
, 18% ground corn stalks, and 5% of a supplement containing decoquinate
j
 (Table 
2.1).  Dietary energy concentrations were increased through day 28 using a 2-ration (starter diet 
and grower diet transition system.  The grower diet was composed of 30% ground corn, 52% wet 
corn gluten feed, 13% ground corn stalks, and 5% of a supplement containing lasalocid
k
 (Table 
2.1).  Feed was delivered to the bunks twice daily by way of an auger mixer wagon.  Throughout 
the feeding period, cattle were offered as close to ad libitum feed as possible to minimize the 
amount of feed left over before the next feeding period.  Cattle and feed bunks were evaluated 
visually twice each day (morning and early afternoon) to determine the quantity of feed to offer 
each pen for the subsequent feeding.  Weekly feed samples were obtained from randomly 
selected bunks to determine dietary dry matter and for proximate analyses.  In addition, at each 
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scheduled weigh period (d 28 and 56), residual feed was collected, weighed, and sampled for dry 
matter to determine dry matter intake. 
 
Animal Health 
Clinical monitoring was completed at the same time each day by trained animal health 
personnel.  Animals were assessed daily through the end of the study based on severity of 
common clinical signs associated with BRD according to the following protocol.  Any animal 
deemed as “sick” was scored as follows: Depression (0 = normal, 1 = mildly depressed, 2 = 
moderately depressed, 3 = severely depressed), Anorexia (Rumen Fill; 0 = normal (at pen 
average or above), 1 = slightly below pen average, 2 = moderately below pen average, 3 = 
severely below pen average), and Respiratory (0 = normal, 1 = compromised – increased rate or 
depth of respiration, 2 = labored – as 1, but open mouth breathing or neck extension, 3 = severe – 
as 2, but severe grunting or thumping).  Any animal pulled with a combined score ≥ 3 and a 
rectal temperature ≥ 104°F was treated with ceftiofur crystalline free acidl, according to label 
directions, and a 5 day moratorium so that no retreatment was allowed until 5 days following the 
original treatment.  Any animal removed from the pen for treatment with a combined score ≥ 3 
and a rectal temperature < 104°F was treated with enrofloxacin
m
, according to label directions, 
and a 3 day post-treatment moratorium.  Any animal removed from the pen for treatment with a 
combined score < 3 was not treated and was returned to its home pen.  Any animal removed 
from the pen for treatment for a second time was treated with ceftiofur crystalline free acid as its 
second treatment; however, if the animal received ceftiofur crystalline free acid as its first 
treatment, then enrofloxacin was used as its second treatment.  Sick animals were returned to 
their home pen following treatment. 
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Statistical Analysis 
Individual weights at processing, pen weights at the end of the trial period, average daily 
pen intake, morbidity, and mortality measurements were recorded.  Average daily gain was 
calculated as the average weight change of calves per pen divided by the length of the trial 
period.  Feed efficiency was measured as the average dry matter intake per calf per pen divided 
by the average daily gain of calves per pen.  Average daily gain and feed efficiency were 
calculated on both deads in and deads out basis across treatment groups.  All data were blocked 
by truck load.  SAS
n
 was used for statistical analysis.  Initial weight, final weight, dry matter 
intake, average daily gain, and feed conversion were measured using mixed model analysis.  
Morbidity, mortality, and retreatments were analyzed using a Wilcoxon Rank-Sum Test.  
Differences between treatments were determined using a protected F-test with an alpha = 0.05; if 
the ANOVA Type III probability was ≤ 0.05, means were separated using a least squares means 
procedure.   
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 Wheat Pasture Study 
Animals 
All animals were treated and handled in accordance with protocols approved by the New 
Mexico State University Institutional Animal Care and Use Committee (# 2011-034). 
 On October 24, 2011, a single load of heifers (n = 120, 393.2 + 28.6 lbs) identified as 
being at high risk to develop BRD arrived at the Clayton Livestock Research Center (CLRC) in 
Clayton, NM.  The heifers consisted of a variety of hide colors and of mixed genetics.  The cattle 
were unloaded and placed in an arrival pen with free-choice access to long-stemmed hay and ad 
libitum access to water.  After 24-48 h rest, cattle were individually processed and trailed to a 
125 acre center-pivot-irrigated wheat pasture.  At processing, each animal was allocated into 
three treatment groups (n = 40) consisting of metaphylactic treatment with either gamithromycin, 
tilmicosin, or tulathromycin.   
 
Treatments 
Treatments consisted of the following: 1) tulathromycin (n = 192; 2.5mg/kg, 1.1 ml/100 
lb), 2) tilmicosin (n = 193; 13.2 mg/kg, 2 ml/100 lb), 3) gamithromycin (n = 194; 6 mg/kg, 1.82 
ml/100 lb).  Cattle were randomly assigned to treatment group and placed in temporary pens.  
During initial processing, each heifer was weighed, vaccinated for BVD (Type I and II), IBR, 
BRSV, and PI3, given a doramectin injection and oral albendazole, and implanted with 100 mg 
progesterone and 10 mg estradiol benzoate.  Each animal received an individual identification 
ear tag, a tag identifying treatment assignment, and any horns, if present were tipped to 
approximately 2.54 cm diameter.  Once processing was completed, all treatment groups were 
trailed approximately one mile to the irrigated wheat pasture.  The individual animal served as 
the experimental unit. 
16 
 
 
Feeding 
Cattle were allowed to graze on irrigated wheat pasture for 54 days.  Water was supplied 
to the pasture with six continuous flow, heated water tanks.  During two instances of extreme 
weather (snow/cold), cattle were supplemented with bales of grass hay.  Three (3) tubs of Hi-
Pro® mineral (900 lbs) with lasalocid (7.2 pounds) allowed for a free-choice mineral and 
ionophore to promote nutrition, growth and control coccidia levels.     
 
Animal Health 
Clinical health monitoring was completed at the same time each day (approximately 0900 
hrs) by trained animal health personnel.  Animals were assessed daily through the end of the 
study based on scoring severity of common clinical signs associated with BRD as explained in 
the feedyard trial.  Animals pulled to treat were trailed to the south end of the pasture to working 
corrals and chute to be assessed and treated.  After treatments, animals were immediately 
returned to pasture. 
 
Statistical Analysis 
Data were entered into Microsoft Excel (2010) throughout the experiment.  Individual 
weights at post-arrival processing and at the end of the trial period, morbidity, and mortality 
measurements were recorded.  Initial weight, final weight, and average daily gain were measured 
using GLM procedure; morbidity and mortality were analyzed using FREQ procedure. 
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 Results 
 
 Feedyard Study 
 
Seven animals were removed from the feedyard study.  Two were removed due to 
lameness; three were removed due to animal welfare concerns based on severe clinical morbidity 
prior to expiration of the assigned moratorium; two were severely anorectic; two were removed 
due to suspected polioencephalomalacia.  The results indicate there were no differences (P = 
0.73) in initial weight among treatment groups (Table 2.2).  However, tulathromycin-treated 
calves tended (P = 0.10) to have greater end weight than gamithromycin treated calves (Table 
2.2). There were no differences (P = 0.20) between treatment groups for the average dry matter 
intake of calves during the trial period (Table 2.2).  On a deads in basis, cattle administered 
tulathromycin had greater (P < 0.01) ADG than cattle administered gamithromycin by 0.29 lbs/d 
and tended (P = 0.09) to have greater ADG than cattle that received tilmicosin by 0.18 lbs/d 
(Table 2.2).  No differences were found between gamithromycin-treated calves and calves 
treated with tilmicosin.  Tulathromycin treated cattle tended (P = 0.12) to have improved feed 
efficiency compared to gamithromycin treated cattle (Table 2.2), with tilmicosin-treated calves 
being intermediate to and not different from the other two treatments.  Results for deads out 
analysis yielded similar results as deads in analysis (Table 2.2).  Calves that received 
tulathromycin (5.2%) had reduced (P < 0.02) morbidity rates than those that received tilmicosin 
(14.6%) and gamithromycin (12.79%; Table 2.3).  No differences were found in morbidity 
between tilmicosin treated calves and gamithromycin treated calves.  Mortality rates were low 
18 
 
across all treatment groups, and there were no treatment differences (Table 2.3) for mortality or 
retreatment rate. 
19 
 
 Wheat Pasture Study 
 
One animal was removed from the study due to being removed from the pasture for three 
days for treatment of clinical coccidiosis.  
Initial body weight did not differ by treatment (P = 0.72; Table 2.4).  In contrast with the 
feedlot study, final weights remained similar among treatment groups (P = 0.90).  Therefore, 
ADG did not differ (P = 0.98) among treatments.  Morbidity and mortality did not differ among 
treatments (P = 0.46 and 0.35, respectively).   
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Discussion 
 
Results from the feedyard study indicate that metaphylactically treating high risk calves 
with tulathromycin upon arrival provided the greatest opportunity to minimize the pathogenic 
effects of BRD.  Results also indicated that there was no difference across all variables in calves 
treated with tilmicosin and calves treated with gamithromycin.  No differences were noted for 
any variable among treatment groups in the wheat pasture study.  Average daily gain for calves 
in all treatment groups were lower than anticipated.  This may be due to adverse weather 
conditions (i.e. extreme cold, snow, and high winds) on two occasions with no shelter provided.  
Without a negative control in which to compare the antibiotics, it is not possible to tell if they 
were effective at mitigating BRD.   
The present study found differing results versus those reported in Sgoifo Rossi et al. In 
that study, cattle treated with gamithromycin had a lower morbidity rate (9.3%) than 
tulathromycin treated cattle (14.6%).
10
  However, in the present feedyard study, tulathromycin 
treated cattle had a lower morbidity rate (5.16%) compared to cattle treated with gamithromycin 
(12.79%; P = 0.02).  On the other hand, the study discussed earlier by Booker et al. that 
compared treatments with tulathromycin and tilmicosin, found similar results as the present 
feedyard study.
11
  Although those authors found differences between tulathromycin and 
tilmicosin for ADG, morbidity, and mortality, the present feedyard study only found a significant 
difference for morbidity, a trend for ADG, and no difference for mortality.     
Results of Van Donkersgooed and Merrill (2012) showed a decrease (P = 0.01) in first-
pull treatment rates for BRD in gamithromycin treated calves than in calves treated with 
tilmicosin.
15
  In both  metaphylactic and non-metaphylactic studies,  treatment with either 
21 
 
tulathromycin or gamithromycin showed no differences across all variables when taken 150 days 
to closeout.
16 
In conclusion, the feedyard study found that high risk cattle treated upon arrival with 
tulathromycin had greater ADG than calves treated with gamithromycin with tilmicosin-treated 
calves being intermediate, and reduced morbidity than cattle treated with tilmicosin or 
gamithromycin; however, for calves being placed on wheat pasture, there were no differences for 
performance or health measures among the treatments used in this study. 
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Table 2.1:  Feedyard supplement composition.  Values listed as percentage of total ration.    
  
Supplement Ingredient Deccox Supplement Bovatec Supplement 
Decoquinate 27.2 g/lb 0.031 0 
Lasalocid 91 g/lb 0 0.015 
Cargill Beefmax 510 0.045 0.045 
Urea 45% Nitrogen 0.25 0.25 
Limestone 1.5 1.5 
Corn distillers grain 2.95 2.95 
Sodium Chloride 0.2 0.2 
Vitamin A/D 1000/200 0.00025 0.00025 
Vitamin E-50 0.006 0.006 
Total 4.98225 4.96625 
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Table 2.2:  Feedyard average initial weights, average out weights, average dry matter 
intake, average daily gain, and feed efficiency for calves in each treatment group.  Deads in 
and deads out analysis.   
 
Treatment Tulathromycin* Tilmicosin* Gamithromycin* SE P 
Avg In Wt, lb 403.5 402.7 405.1 3.29
 
0.73 
Avg Out Wt, lb 553.0
a 
544.3
ab 
540.1
b 
8.28
 
0.10 
DMI, lb 12.52 12.28 11.99 0.20
 
0.20 
ADG, lb      
Deads In 2.54
a 
2.36
ab 
2.25
b 
0.11 0.03 
Deads Out 2.62
a 
2.48
ab 
2.36
b 
0.09 0.02 
F:G      
Deads In 4.96 5.29 5.43 0.26 0.27 
Deads Out 4.82 5.01 5.10 0.17 0.27 
 * Values within a row with different superscripts are significantly different (P < .05). 
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Table 2.3:  Feedyard morbidity, mortality, and retreatments per pen of each treatment 
group.   
 
Treatment Tulathromycin* Tilmicosin* Gamithromycin* P 
Mortality 1.02% 1.55% 1.53% 0.93 
Morbidity 5.16%
a 
14.62%
b 
12.79%
b 
0.02 
Retreats 0.00% 2.56% 1.50% 0.16 
*Values within a row with different superscripts are significantly different (P < .05). 
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Table 2.4:  Wheat pasture average initial weights, average out weights, and average daily 
gain for calves in each treatment group.   
 
Treatment Tulathromycin* Tilmicosin* Gamithromycin* SE P 
Avg In Wt, lb 395.9 390.6 392.7 6.50 0.72 
Avg Out Wt, lb 452.9 447.9 449.7 10.87 0.90 
ADG, lb 1.07 1.08 1.06 0.13 0.98 
 * No significant difference found among values (P > .05).   
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Table 2.5:  Wheat pasture morbidity and mortality rates of each treatment group.   
 
Treatment Tulathromycin* Tilmicosin* Gamithromycin* P 
Mortality     
No. of Head 2 2 5 0.35 
Percentage 5.13% 5.00% 12.5%  
Morbidity 
   
 
No. of Head 2 5 5 0.46 
Percentage 5.13% 12.50% 12.50%  
 * No significant difference found among values (P > .05). 
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Appendix A - Product Index 
a
Draxxin, Pfizer Animal Health, New York, NY. 
b
Micotil, Eli Lilly and Company, Indianapolis, IN.
 
c
Zactran, Merial LTD, Duluth, GA. 
d
Bovishield Gold 5, Pfizer Animal Health, New York, NY.  
e
Inforce 3, Pfizer Animal Health, New York, NY. 
f
Dectomax, Pfizer Animal Health, New York, NY. 
g
Valbazen, Pfizer Animal Health, New York, NY. 
h
Synovex C, Pfizer Animal Health, New York, NY. 
i
Sweet Bran, Cargill Inc., Blair, NE. 
j
Deccox, Pfizer Animal Health, New York, NY. 
k
Bovatec, Pfizer Animal Health, New York, NY. 
l
Excede, Pfizer Animal Health, New York, NY. 
m
Baytril 100, Bayer Animal Health, Shawnee Mission, KS. 
n
SAS, ver. 9.1.3; SAS Institute, Cary, NC. 
 
